CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Cancer Network
Original article

<![CDATA[ctDNA MRD Guidance in Bladder Cancer: Pharmacy Specialist on NCCN Updates]]>

RegulatoryNeutral
AI Analysis

Summary

NCCN updated guidelines for bladder cancer to incorporate ctDNA MRD testing to guide adjuvant immunotherapy decisions and improve event-free survival outcomes.

Importance:3/10
Sentiment:
0.00
ctDNAMRD testingbladder cancerNCCN guidelinesadjuvant immunotherapyevent-free survival

Read the original article

Published by Cancer Network on July 19, 2026 6:00 PM

Read Original